Nuance Enters $58 Million Deal for Non-Opioid Pain Treatment in China

Nuance Biotech of Shanghai in-licensed China rights to a non-opioid treatment for long-lasting pain following surgery from US-based Pacira Pharma in a $58 million agreement. Nuance will pay $3 million upfront and the rest in milestones, plus royalties. Nuance plans to file a Clinical Trial Application in China later this year. Pacira describes Exparel® (bupivacaine liposome injectable suspension) as an anesthesia deposited at the site during surgery or administered as an interscalene brachial plexus nerve block. More details.... Stock Symbol: (NSDQ: PCRX) Share this with colleagues: // //